Original Article

Scanning all chromosomal abnormalities with microarray-based comparative genomic hybridization in differential diagnosis of pediatric cancers

Hulya Tosun Yildirim¹, Safiye Aktas², Gulden Diniz³, Tekincan Cagri Aktas², Burcin Baran², Serdar Bayrak², Zekiye Altun², Yasemin Cakir², Nur Olgun²

¹Department of Pathology, Antalya Education and Research Hospital, Health Sciences University, Antalya, Turkey; ²Oncology Institute, Department of Basic Oncology, Dokuz Eylul University, Izmir, Turkey; ³Department of Pathology, Izmir Democracy University, Izmir, Turkey

Received May 28, 2019; Accepted July 22, 2019; Epub August 1, 2019; Published August 15, 2019

Abstract: Objective: Despite conventional histopathological and immunohistochemical methods, difficulties may be experienced in the differential diagnosis of pediatric cancers, especially in small round-cell undifferentiated tumors. In these cases, the determination of chromosomal abnormalities may be helpful. The aim of this study was to evaluate the place of the whole genome array comparative genomic hybridization method in pediatric cancers where difficulty is experienced in differential diagnosis. Method: In Comparative Genomic Hybridization (CGH), 135,000 probes were scanned as 3 probes per gene in all genomes. It was possible to analyze paraffin block tissues obtained from the archive of the Pathology Laboratory of Dr. Behcet Uz Children's Hospital. DNA extraction was made from the paraffin blocks of 24 cases where difficulty had been experienced in making the differential diagnosis and in each case, comparisons with the control samples were made for all anomalies in all chromosomes using microarray technology. Results: Together with the typically observed chromosomal anomalies, additional derangements with debatable importance were determined. Conclusion: The whole genome CGH method may be useful in pediatric cancers where difficulties are experienced in making differential diagnoses. Since technical difficulties are experienced in the examination of paraffin-embedded tissue samples, storing fresh tissue samples from each tumor will be helpful for genetic and molecular examinations.

Keywords: Comparative genomic hybridization (CGH), pediatric cancers, small round cell malignant tumors, differential diagnosis

Introduction

Malignancies are one of the important causes of death in children. In developed countries, less than one percent of cancers occur in children under 15 years of age. The overall cancer prevalence is between 70-160 per million people under the age of 15 years [1]. In developing countries such as our country, malignancies are the fourth most common cause of death. Differential diagnosis is more important in childhood malignancies because of the longer life expectancy of children [1].

Primitive small round cell tumors observed in childhood belong to heterogeneous malignant tumor groups that constitute 0.1% of childhood

malignant tumors. These tumors mainly seen in childhood may be listed as neuroblastoma, sarcomas, including rhabdomyosarcomas, non-rhabdomyosarcoma soft tissue sarcomas, Ewing sarcoma (ES)/primitive neuroectodermal tumor (PNET), desmoplastic small round cell tumor (DSRCT) and malignant rhabdoid/teratoid tumor (RT) [1-3].

The whole genome-comparative genomic hybridization technique is a cytogenetic method based on FISH demonstrating fluorescent color differences obtained by a linking test (patient), and reference DNA samples stained with different fluorescent dyes to normal chromosomes. With this method, structural chromosomal anomalies that cannot be detected by standard

techniques can be identified more reliably, allowing both the comparison of at least two genomes with each other and the analysis of the whole genome in a single experiment [4-6].

The aim of this study is to investigate the role of whole genome-comparative genomic hybridization in pediatric cancers posing difficulties in differential diagnosis.

Materials and methods

In the Pathology Laboratory of Dr. Behçet Uz. Children's Hospital, DNA samples were extracted from the paraffin blocks of 24 patients where difficulty was experienced in the differential diagnosis, and a CGH analysis was performed. The anticipated chromosomal anomalies were compared with the clinicopathological findings.

In the comparative genomic hybridization analysis, the differences in the number of copies in the whole genome or in a region on the genome with a referenced genome were determined using NimbleGen CGH arrays. The DNA of 24 patients (test DNA) and normal DNA (control DNA) to be analyzed for CGH were labeled with different fluorochromes and hybridized with metaphase chromosomes obtained from normal cells. Differences in fluorescence intensities across chromosomes in the reference metaphase domain refer to the differences in the number of copies (amplifications or deletions) in the tumor DNA. If DNAs showing different fluorescent phenotypes overlap with normal metaphase chromosomes, they are have a blue-orange color.

If there is a deletion in the test DNA, hybridization does not occur in this region, so this region appears red. In contrast, if there is an amplification in the DNA, the region is appears green and is brighter than the other regions because hybridization is more intense in this region. Chromosome hybridization profiles were calculated according to hybridization rates using a special image analysis software program.

Results

Our study population consisted of patients with Ewing sarcomas (n = 10), neuroblastomas (n = 5), and undifferentiated malignant tumors (n = 9) (**Table 1**). Previous diagnoses of RT (n = 2), DSRCT (n = 2), and RMS (n = 1) were considered in 5 cases with diagnoses of undifferenti-

ated malignant tumors. The ages of the patients ranged from 2 months to 18 years. The mean age of the patients was 8.7 ± 5.3 years. The series consisted of 10 boys (41.7%) and 14 girls (58.3%). The tumors were localized in the kidneys and adrenal glands (n = 6), the abdominal cavity (n = 4), the chest wall (n = 4), the soft tissue of the hip or of an extremity (n = 3), the lungs or pleura (n = 2), the pelvic region (n = 2), and the liver (n = 1). The location of the tumor was unknown in 2 cases sent for the consultation (**Table 1**).

In all, 3 male and 7 female Ewing sarcoma patients were analyzed (**Figure 1**). The median age of the patients was 8. 6 years. The oldest and the youngest patients were 14 years and 1 year old, respectively. The tumors were located in different body parts. These tumors were localized in the extremities (n = 2), the lungs (n = 1), and in the soft tissue of the trunk (n = 7). The CGH analysis frequently detected 8 gene domains (commonly shared gene domains found in 6 and 7 cases with Ewing sarcoma) (**Table 2**).

In our series, 1 male, and 4 female patients with a median age of 7.2 years (range, 2-16 years) received the diagnosis of undifferentiated neuroblastoma. The tumors were localized in the adrenal glands in 3 cases. In the CGH analysis, 8 gene regions (commonly shared in 4 or 5 of 9 cases) were often detected (**Table 3**).

In addition, 9 cases were diagnosed as undifferentiated malignant tumors. Among the cases diagnosed as undifferentiated tumors, the previous diagnoses of RT (n=2), DSCRT (n=2), and RMS (n=1) were considered. In the CGH analysis, 8 gene regions (commonly shared in 4 or 5 of 9 cases) were often detected (**Table 4**).

Discussion

Due to the heterogeneous structure of the primitive small round cell tumors, the limitation in the number of tissue specimens sampled in the biopsy, and the overlapping morphological and even immunohistochemical findings, the differential diagnosis may be challenging. Therefore, molecular analyses may be needed for the diagnosis of these tumors [7]. A single translocation or deletion analyzed with a single probe may not always yield precise results. Because the chromosomal anomaly in question may not be of a uniform type, variations

Table 1. Patient demographic data

1 1A1 4 F Iliac bone region Ewing sarcoma Not know 2 1A2 4 M Abdomen Undifferentiated malignant tumor Not know 3 1A3 11 M Thoracic wall Ewing sarcoma Not know 4 1A4 9 M Pelvic region Undifferentiated malignant tumor Not know 5 1A5 8 M Sacral region Ewing sarcoma Died 6 1A6 0 F Liver Undifferentiated malignant tumor Not know 7 1A7 18 F Not known Ewing sarcoma Died 8 1A8 17 F Not known Ewing sarcoma Died 9 1A9 13 M Lung/pleura Undifferentiated malignant tumor Died 1A10 2,5 F Pelvic region Undifferentiated malignant tumor Not know 11 1A11 10 F Kidney Undifferentiated malignant tumor Not know 12 1A12 7 F Thoracic wall Ewing sarcoma Not know 13 2A1 13 F Abdomen Ewing sarcoma Not know 14 2A2 3 M Kidney Undifferentiated malignant tumor Died 15 2A3 3 M Kidney Undifferentiated malignant tumor Died 16 2A4 15 M Shoulder Ewing sarcoma Alive 17 2A5 15 F Lung/pleura Ewing sarcoma Died 18 2A6 14 F Thoracic wall Ewing sarcoma Alive	CACE	CACE NUMBER	ACE (11224)	CEV	LOCATION	DIACNOCIC	CLIDV/IV/AL
21A24MAbdomenUndifferentiated malignant tumorNot known31A311MThoracic wallEwing sarcomaNot known41A49MPelvic regionUndifferentiated malignant tumorNot known51A58MSacral regionEwing sarcomaDied61A60FLiverUndifferentiated malignant tumorNot known71A718FNot knownEwing sarcomaDied81A817FNot knownEwing sarcomaDied91A913MLung/pleuraUndifferentiated malignant tumorNot known101A102,5FPelvic regionUndifferentiated malignant tumorNot known111A1110FKidneyUndifferentiated malignant tumorNot known121A127FThoracic wallEwing sarcomaNot known132A113FAbdomenEwing sarcomaNot known142A23MKidneyUndifferentiated malignant tumorDied152A33MKidneyUndifferentiated malignant tumorDied162A415MShoulderEwing sarcomaAlive172A515FLung/pleuraEwing sarcomaAlive182A614FThoracic wallEwing sarcomaAlive	CASE			SEX	LOCATION	DIAGNOSIS	SURVIVAL
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	1		4		Iliac bone region	· ·	Not known
4 1A4 9 M Pelvic region Undifferentiated malignant tumor Not know 5 1A5 8 M Sacral region Ewing sarcoma Died 6 1A6 0 F Liver Undifferentiated malignant tumor Not know 7 1A7 18 F Not known Ewing sarcoma Alive 8 1A8 17 F Not known Ewing sarcoma Died 9 1A9 13 M Lung/pleura Undifferentiated malignant tumor Died 10 1A10 2,5 F Pelvic region Undifferentiated malignant tumor Not know 11 1A11 10 F Kidney Undifferentiated malignant tumor Not know 12 1A12 7 F Thoracic wall Ewing sarcoma Not know 13 2A1 13 F Abdomen Ewing sarcoma Not know 14 2A2 3 M Kidney Undifferentiated malignant tumor Died 15 2A3 3 M Kidney Undifferentiated malignant tumor Died 16 2A4 15 M Shoulder Ewing sarcoma Alive 17 2A5 15 F Lung/pleura Ewing sarcoma Died 18 2A6 14 F Thoracic wall Ewing sarcoma Alive	2	1A2	4	M	Abdomen	Undifferentiated malignant tumor	Not known
5 1A5 8 M Sacral region Ewing sarcoma Died 6 1A6 0 F Liver Undifferentiated malignant tumor Not known 7 1A7 18 F Not known Ewing sarcoma Alive 8 1A8 17 F Not known Ewing sarcoma Died 9 1A9 13 M Lung/pleura Undifferentiated malignant tumor Died 10 1A10 2,5 F Pelvic region Undifferentiated malignant tumor Not known 11 1A11 10 F Kidney Undifferentiated malignant tumor Not known 12 1A12 7 F Thoracic wall Ewing sarcoma Not known 13 2A1 13 F Abdomen Ewing sarcoma Not known 14 2A2 3 M Kidney Undifferentiated malignant tumor Died 15 2A3 3 M Kidney Undifferentiated malignant tumor Died 16 2A4 15 M Shoulder Ewing sarcoma Alive 17 2A5 15 F Lung/pleura Ewing sarcoma Died 18 2A6 14 F Thoracic wall Ewing sarcoma Alive	3	1A3	11	M	Thoracic wall	Ewing sarcoma	Not known
6 1A6 0 F Liver Undifferentiated malignant tumor Not known 7 1A7 18 F Not known Ewing sarcoma Alive 8 1A8 17 F Not known Ewing sarcoma Died 9 1A9 13 M Lung/pleura Undifferentiated malignant tumor Died 10 1A10 2,5 F Pelvic region Undifferentiated malignant tumor Not known 11 1A11 10 F Kidney Undifferentiated malignant tumor Not known 12 1A12 7 F Thoracic wall Ewing sarcoma Not known 13 2A1 13 F Abdomen Ewing sarcoma Not known 14 2A2 3 M Kidney Undifferentiated malignant tumor Died 15 2A3 3 M Kidney Undifferentiated malignant tumor Died 16 2A4 15 M Shoulder Ewing sarcoma Alive 17 2A5 15 F Lung/pleura Ewing sarcoma Died 18 2A6 14 F Thoracic wall Ewing sarcoma Alive	4	1A4	9	M	Pelvic region	Undifferentiated malignant tumor	Not known
7 1A7 18 F Not known Ewing sarcoma Alive 8 1A8 17 F Not known Ewing sarcoma Died 9 1A9 13 M Lung/pleura Undifferentiated malignant tumor Died 10 1A10 2,5 F Pelvic region Undifferentiated malignant tumor Not know 11 1A11 10 F Kidney Undifferentiated malignant tumor Not know 12 1A12 7 F Thoracic wall Ewing sarcoma Not know 13 2A1 13 F Abdomen Ewing sarcoma Not know 14 2A2 3 M Kidney Undifferentiated malignant tumor Died 15 2A3 3 M Kidney Undifferentiated malignant tumor Died 16 2A4 15 M Shoulder Ewing sarcoma Alive 17 2A5 15 F Lung/pleura Ewing sarcoma Died 18 2A6 14 F Thoracic wall Ewing sarcoma	5	1A5	8	M	Sacral region	Ewing sarcoma	Died
8 1A8 17 F Not known Ewing sarcoma Died 9 1A9 13 M Lung/pleura Undifferentiated malignant tumor Died 10 1A10 2,5 F Pelvic region Undifferentiated malignant tumor Not know 11 1A11 10 F Kidney Undifferentiated malignant tumor Not know 12 1A12 7 F Thoracic wall Ewing sarcoma Not know 13 2A1 13 F Abdomen Ewing sarcoma Not know 14 2A2 3 M Kidney Undifferentiated malignant tumor Died 15 2A3 3 M Kidney Undifferentiated malignant tumor Died 16 2A4 15 M Shoulder Ewing sarcoma Alive 17 2A5 15 F Lung/pleura Ewing sarcoma Died 18 2A6 14 F Thoracic wall Ewing sarcoma	6	1A6	0	F	Liver	Undifferentiated malignant tumor	Not known
9 1A9 13 M Lung/pleura Undifferentiated malignant tumor Died 10 1A10 2,5 F Pelvic region Undifferentiated malignant tumor Not know 11 1A11 10 F Kidney Undifferentiated malignant tumor Not know 12 1A12 7 F Thoracic wall Ewing sarcoma Not know 13 2A1 13 F Abdomen Ewing sarcoma Not know 14 2A2 3 M Kidney Undifferentiated malignant tumor Died 15 2A3 3 M Kidney Undifferentiated malignant tumor Died 16 2A4 15 M Shoulder Ewing sarcoma Alive 17 2A5 15 F Lung/pleura Ewing sarcoma Died 18 2A6 14 F Thoracic wall Ewing sarcoma	7	1A7	18	F	Not known	Ewing sarcoma	Alive
10 1A10 2,5 F Pelvic region Undifferentiated malignant tumor Not know 11 1A11 10 F Kidney Undifferentiated malignant tumor Not know 12 1A12 7 F Thoracic wall Ewing sarcoma Not know 13 2A1 13 F Abdomen Ewing sarcoma Not know 14 2A2 3 M Kidney Undifferentiated malignant tumor Died 15 2A3 3 M Kidney Undifferentiated malignant tumor Died 16 2A4 15 M Shoulder Ewing sarcoma Alive 17 2A5 15 F Lung/pleura Ewing sarcoma Died 18 2A6 14 F Thoracic wall Ewing sarcoma Alive	8	1A8	17	F	Not known	Ewing sarcoma	Died
11 1A11 10 F Kidney Undifferentiated malignant tumor Not know 12 1A12 7 F Thoracic wall Ewing sarcoma Not know 13 2A1 13 F Abdomen Ewing sarcoma Not know 14 2A2 3 M Kidney Undifferentiated malignant tumor Died 15 2A3 3 M Kidney Undifferentiated malignant tumor Died 16 2A4 15 M Shoulder Ewing sarcoma Alive 17 2A5 15 F Lung/pleura Ewing sarcoma Died 18 2A6 14 F Thoracic wall Ewing sarcoma Alive	9	1A9	13	M	Lung/pleura	Undifferentiated malignant tumor	Died
12 1A12 7 F Thoracic wall Ewing sarcoma Not known 13 2A1 13 F Abdomen Ewing sarcoma Not known 14 2A2 3 M Kidney Undifferentiated malignant tumor Died 15 2A3 3 M Kidney Undifferentiated malignant tumor Died 16 2A4 15 M Shoulder Ewing sarcoma Alive 17 2A5 15 F Lung/pleura Ewing sarcoma Died 18 2A6 14 F Thoracic wall Ewing sarcoma Alive	10	1A10	2,5	F	Pelvic region	Undifferentiated malignant tumor	Not known
13 2A1 13 F Abdomen Ewing sarcoma Not know 14 2A2 3 M Kidney Undifferentiated malignant tumor Died 15 2A3 3 M Kidney Undifferentiated malignant tumor Died 16 2A4 15 M Shoulder Ewing sarcoma Alive 17 2A5 15 F Lung/pleura Ewing sarcoma Died 18 2A6 14 F Thoracic wall Ewing sarcoma Alive	11	1A11	10	F	Kidney	Undifferentiated malignant tumor	Not known
142A23MKidneyUndifferentiated malignant tumorDied152A33MKidneyUndifferentiated malignant tumorDied162A415MShoulderEwing sarcomaAlive172A515FLung/pleuraEwing sarcomaDied182A614FThoracic wallEwing sarcomaAlive	12	1A12	7	F	Thoracic wall	Ewing sarcoma	Not known
15 2A3 3 M Kidney Undifferentiated malignant tumor Died 16 2A4 15 M Shoulder Ewing sarcoma Alive 17 2A5 15 F Lung/pleura Ewing sarcoma Died 18 2A6 14 F Thoracic wall Ewing sarcoma Alive	13	2A1	13	F	Abdomen	Ewing sarcoma	Not known
162A415MShoulderEwing sarcomaAlive172A515FLung/pleuraEwing sarcomaDied182A614FThoracic wallEwing sarcomaAlive	14	2A2	3	M	Kidney	Undifferentiated malignant tumor	Died
17 2A5 15 F Lung/pleura Ewing sarcoma Died 18 2A6 14 F Thoracic wall Ewing sarcoma Alive	15	2A3	3	M	Kidney	Undifferentiated malignant tumor	Died
18 2A6 14 F Thoracic wall Ewing sarcoma Alive	16	2A4	15	M	Shoulder	Ewing sarcoma	Alive
	17	2A5	15	F	Lung/pleura	Ewing sarcoma	Died
19 2A7 5 M Abdomen Undifferentiated malignant tumor Alive	18	2A6	14	F	Thoracic wall	Ewing sarcoma	Alive
	19	2A7	5	M	Abdomen	Undifferentiated malignant tumor	Alive
20 2A8 7 F Adrenal gland Neuroblastoma Alive	20	2A8	7	F	Adrenal gland	Neuroblastoma	Alive
21 2A9 16 F Abdomen Neuroblastoma Not know	21	2A9	16	F	Abdomen	Neuroblastoma	Not known
22 2A10 2 M Adrenal gland Neuroblastoma Alive	22	2A10	2	M	Adrenal gland	Neuroblastoma	Alive
23 2A11 7 F Adrenal gland Neuroblastoma Alive	23	2A11	7	F	Adrenal gland	Neuroblastoma	Alive
24 2A12 5 F Thoracic wall Neuroblastoma Alive	24	2A12	5	F	Thoracic wall	Neuroblastoma	Alive




Figure 1. (A) General appearence of ES/PNET tumor cells (HE \times 200). Immunohistochemical stains in the same tumor: (B) Ki67 proliferation index, (C) Expression of CD99 (DAB \times 200), and (D) Expression of Synaptophysin (DAB \times 200).

can be found, or, it may be necessary to look at multiple sites for the differential diagnosis. In

these cases, CGH may help detect chromosomal anomalies [6].

In our ES/PNET patient cohort, the number of copies were most often altered in genes srGAP2, RGPD5, NPHP1, GTF-2IRD2, PDXDC1. srGAP2 is a member of the SLIT-ROBO Rho GTPase activating protein family, which regulates cell differentiation and neuronal migration. The gene is also located in region 1q. The deletions in 1q regions were also observed in previously performed CGH analyses [8]. RGDP5 is a nuclear membrane-associated protein that regulates cellular functions through interactions with other proteins. NPHP1

interacts with Crk-associated substrates and controls cell division, cell-cell, and cell-matrix

CGH in pediatric cancers

 Table 2. Copy number altered genes among patients with ES/PNET

CVMPOL	GENE NAME	LOCATION	1 1 1	112	1 1 5	117	110	1110	244	244	OAE	246	Total
SYMBOL	GENE NAME	LOCATION	1A1	1A3	1A5	1A7	1A8	1A12	2A1	2A4	2A5	2A6	Total
srGAP2	SLIT-ROBO Rho GTPase-activating protein 2	1q32.1	del	del	del	del	del	Χ	del	del	Х	Χ	7/10
RGPD5	RANBP2-like and GRIP domain containing 5	2q13	del	del	Х		del	del	del	del	del	Х	7/10
NPHP1	nephrocystin 1	2q13	del	Х	Х	del	del	del	del	del	del	Х	7/10
GTF2IRD2	GTF2I repeat domain containing 2	7q11.23	del	del	Х	del	Х	del	del	del	amp	Х	7/10
PDXDC1	pyridoxal dependent decarboxylase domain containing 1	16p13.11	del	del	Х	del	del	del	Х	del	del	Х	7/10
MALL	T cell differentiation protein like	2q13	del	del	del	del	del	Х	del	Х	Х	Х	6/10
ANKRD30A	Ankyrin repeat domain 30A	10p11.21	del	del	Χ	del	Х	del	Х	del	del	Х	6/10
PTPN20	PTPN20 protein tyrosine phosphatase, non-receptor type 20	10q11.21	del	del	del	Х	del	Х	Х	del	del	Х	6/10
USP22	ubiquitin specific peptidase 22	17p11.2	х	del	Х	del	х	del	del	del	del	х	6/10

Table 3. Copy number changes among patients with neuroblastoma

SYMBOL	GENE NAME	LOCATION	2A8	2A9	2A10	2A11	2A12	Total
DEFB107A	Defensin beta 107A	8p23.1	del	del	del	del	del	5/5
MAGEA12	MAGE family member A12	Xq28	del	del	Х	del	del	4/5
SPANXD	SPANX family member D	Xq27.2	del	х	del	del	del	4/5
SAGE1	sarcoma antigen 1	Xq26.3	del	del	del	del	Х	4/5
DEFB106A	Defensin beta 106A	8p23.1	Х	del	del	del	del	4/5
DEFB103B	Defensin beta 103B	8p23.1	del	del	del	Х	del	4/5
RGPD5	RANBP2 like and GRIP domain containing 5	2q13	del	del	Х	del	del	4/5

adhesion signaling. GTF2IRD2 is a transcriptional factor under the control of the retinoblastoma protein.

MALL participates in raft-mediated trafficking in endothelial cells. MAL1 interacts with caveolin and is localized in glycolipid or cholesterolenriched membrane rafts. PTPN20 is a member of the protein tyrosine phosphatases and is involved in actin polymerization. USP22 is an interesting gene that regulates various cellular and organismal processes such as cell proliferation, apoptosis, and malignant transformation. It also deubiquitinates histones H2A and H2B, thereby acting as a coactivator. USP22 participates in the activation of several oncogenes such as MYC and contributes to stemness in colorectal carcinogenesis as well as the epithelial mesenchymal transition in osteosarcoma cell lines. Altered levels of ANKRD30A expressed in epithelial cells and in the testes have been found to be associated with breast cancer. TPTE is a PTEN-related tyrosine phosphatase and plays a role in the endocrine signal transduction pathways and in the spermatogenic function of the testes. CTSE encodes peptidase involved in antigen processing and the maturation of secretory proteins [1, 8].

Even with the availability of advanced molecular and immunohistochemical diagnostic methods, the diagnosis of poorly differentiated and undifferentiated neuroblastomas may be especially difficult. The defensin beta 107A gene, where copy number variations were most frequently detected in the CGH analysis performed in our patient series, and the defensin family produced by neutrophils, are antimicrobial, and cytotoxic peptides are effective on the immune system. There is evidence that abnormal defensin expression is related to a susceptibility to infectious diseases and inflammatory disorders. The loss/deletion of defensin beta

107A has been especially observed in breast, cervix, colon, and bladder cancers [10-12].

The MAGE family member A12 gene is closely related to several other genes clustered on the X chromosome. It has been reported that these genes may be overexpressed in melanoma and breast cancer tumors [13, 14]. However, in our study, a deletion was detected in the MAGE family member A12 gene in neuroblastoma cases. The SPANX family member D sarcoma antigen 1 plays a role in the formation of mature spermatozoa. It is necessary to initiate the sequence of molecular and morphological changes in the germ cells. This gene is a member of the gene family associated with the SPA-NX cancer/testis localized in a cluster on the X chromosome. SPANX genes encode diversely differentiated testis-specific proteins that are localized in different subcellular compartments. Although the specific function of this gene has not yet been determined, polymorphisms in this gene may be associated with a susceptibility to prostate and breast cancer [15, 16].

Defensin beta 106A is an interesting gene that regulates the processes of stimulating the immune system, especially in the acquired immune response [17]. Defensin beta 103B is also effective in the immune system. A betadefensin 3, expressed in the epithelium in response to various stimulations, including human papilloma virus infection, has recently been found to be overexpressed in head and neck cancers and cervical cancers and has been shown to exhibit tumorigenic activities [17, 18]. However, the RGPD5 gene is a small GTP binding protein of the RAS superfamily, thought to control various cellular functions associated with nuclear membranes and interactions with other proteins. Its relationship with cancerogenesis has not been detected yet [19].

CGH in pediatric cancers

Table 4. Copy number changes among patients with undifferentiated malignant tumors

SYMBOL	GENE NAME	LOCATION	1A2	1A4	1A6	1A9	1A10	1A11	2A2	2A3	2A7	Total
ANKRD30B	ankyrin repeat domain 30B	18p11.21	del	Χ	Χ	del	del	del	del	Х	Х	5/9
SLC6A4	solute carrier family 6 member 4	17q11.2	del	del	Х	Х	del	del	del	Х	Х	5/9
PPIB	peptidylprolyl isomerase B	15q22.31	del	del	Х	del	Х	del	del	Х	Χ	5/9
HERC2	HECT and RLD domain containing E3 ubiquitin protein ligase 2	15q13.1	del	del	Х	del	del	del	Х	Х	Χ	5/9
TD02	tryptophan 2,3-dioxygenase	4q32.1	amp	amp	Х	del	del	del	Х	Х	Χ	5/9
IGSF21	immunoglobin superfamily member 21	1p36.13	Х	Х	Х	del	del	Х	del	del	Χ	4/9
CAMK2B	calcium/calmodulin dependent protein kinase II beta	7p13	Х	Х	Х	del	del	Х	del	del	Χ	4/9
POM121	POM121 transmembrane nucleoporin	7q11.23	del	Х	Х	del	del	del	Х	Х	х	4/9

Difficulties encountered in making the differential diagnoses of undifferentiated malignant tumors, especially in the group of small round cell malignant tumors should be expected. Even immunohistochemical and molecular tests may not show the cases' degrees of differentiation. In such cases, the CGH analysis can be used both to detect DNA copy number variations and to make a differential diagnosis. In 9 cases of our patient series, we could not arrive at a definite differential diagnosis. The immunoglobulin superfamily member 21 gene, which is one of the genes most frequently demonstrating copy number variations in the CGH analysis, encodes a protein that is a member of the immunoglobulin superfamily. These proteins are usually found in cell membranes and act as receptors in immune response pathways. Its association with carcinogenesis has not been determined yet [20].

The product of the calcium/calmodulin-dependent protein kinase II beta (CAMK2B) gene belongs to the serine/threonine protein kinase family and the Ca (2+)/calmodulin-dependent protein kinase subfamily. Calcium signaling is very important for many different aspects of plasticity in glutamatergic synapse. In one study, the dysfunction of CAMK2B was associated with osteoblastic bone metastases of the prostate, and it is closely related to osteoblastogenesis of human mesenchymal stem cells [21]. POM121 transmembrane nucleoporin is a component of the nuclear pore complex (NPC). The NPC functions in the regulation of nucleuscytoplasmic transport, transcription, and the stability of the genome. However, their functional roles in cancer have been poorly understood. There is evidence in the literature that NPC may play a role in the development of primary metastatic prostate cancer [22].

Ankyrin repeat domain 30B gene expression is contained in the testes. The solute carrier family 6 member gene expresses the integral membrane protein that transports serotonin from synaptic domains to presynaptic neurons. It encodes a transport protein that mediates the uptake of long-chain fatty acids in the cell. The function of these proteins is mainly related to lipid biosynthesis, the fatty acid metabolic process, and fatty acid transport. It has been shown to play a role in depression sensitivity in people with aggressive behavior and emotional trauma, especially in Alzheimer's patients. In

addition, the deletion of this gene may contribute to the development of breast and thyroid cancer and may be effective in reducing survival in patients with colorectal cancer [23-25]. Peptidylprolyl isomerase B, a gene product cyclophilin B (CypB), is an endoplasmic reticulum protein that binds to cyclophilin A, which is a member of the cyclophilin family [26, 27]. CypB has peptidyl-prolyl cis-trans isomerase (PPIase) activity. PPlases catalyze the cis-trans isomerization of proline and peptide bonds in oligopeptides and accelerate the folding of proteins. The encoded protein is a cyclophilin A (CypA) binding protein and may play a role in cyclophilin mediated immunosuppression. CypA, the protein produced by this gene, has been reported to be upregulated in breast, stomach, cervical, and pancreatic cancers [28-31]. In particular, it has been reported to regulate the growth and survival of gastric cancer cells and may be related to the recovery of tumor growth and anti-apoptotic functions, and it has been noted as a very important link in the pathogenesis of cancer [26]. In addition, the overexpression of CypB inhibits the activation of antioxidant enzymes in the cell and the resulting reduction of oxidative stress, especially the neurogenic cytotoxicity by mitogen-activated protein kinase through the c-Jun N-terminal kinase pathway [27].

The RLD domain-containing E3 ubiquitin protein ligase 2 gene (HERC2) belongs to the HERC gene family, which encodes a very large group of proteins containing a large number of structural domains. The mutation of the HERC2 gene leads to severe neurodevelopmental disorders. Furthermore, in non-small cell lung cancer, HERC2 facilitates the incorporation of the RNF8-UBC13 complex so as to introduce BRCA1 to DNA damage sites. Moreover, its association with cancer development has been reported [32]. The tryptophan 2.3-dioxygenase (TDO2) gene encodes a heme enzyme that plays a critical role in tryptophan metabolism. The increased activity of the encoded protein and the subsequent production of kynurenine may also play a role in cancer by suppressing antitumor immune responses. In one study, the overexpression of TD02 was observed in the cancer stem cells of esophageal squamous cell carcinoma, and its probable association with poor prognosis was noted [33, 34].

In conclusion, the CGH array may be a useful method for the detection of DNA copy number alterations among pediatric patients with undifferentiated malignant tumors. In our ES/PNET dataset, the copy number alterations were mostly found in genes related to cytoskeletal elements, migration, and protein trafficking in our cohort.

Changes in the number of copies in our neuroblastoma series were mostly found in genes that regulate the stimulation of the immune system [11, 12, 17, 18]. Changes in the number of copies of undifferentiated malignant tumors were found in genes that may be important in mesenchymal stem cell differentiation and in genes that may have played a role in tumor development through the suppression of immune responses and that may cause oxidative stress [21, 26-31]. In order to better understand the role of these genes in tumorigenesis and their contribution to the differential diagnosis, it is necessary to examine the functions of genes in larger series.

Acknowledgements

This text has been edited by Gurkan Kazanci, a professional translator from Logos Publishing. The study was supported by Turkish Pediatric Oncology Group (TPOG).

Disclosure of conflict of interest

None.

Address correspondence to: Dr. Gulden Diniz, Department of Pathology, Izmir Democracy University Medical School, 13. sok. No: 2 Guzelyali, 35290, Izmir, Turkey. Tel: +90 542 2431309; Fax: +90 232 3625522; E-mail: gulden.diniz@idu.edu.tr; agdiniz@gmail.com

References

- [1] Rajwanshi A, Srinivas R, Upasana G. Malignant small round cell tumors. J Cytol 2009; 26: 1-10.
- [2] Merchant MS, Mackall CL. Current approach to pediatric soft tissue sarcomas. Oncologist 2009; 14: 1139-53.
- [3] Kapoor G, Das K. Soft tissue sarcomas in children. Indian J Pediatr 2012; 79: 936-42.
- [4] King W, Proffitt J, Morrison L, Piper J, Lane D, Seelig S. The role of fluorescence in situ hybridization technologies in molecular diagnos-

- tics and disease management. Mol Diagn 2000; 5: 309-19.
- [5] Lau CY. Molecular pathology in cancer research. In: Lakhani SR, Fox SB, editors. New York, U.S.A.: Springer; 2016.
- [6] Bryndorf T, Kirchhoff M, Rose H, Maahr J, Gerdes T, Karhu R, Kallioniemi A, Christensen B, Lundsteen C, Philip J. Comparative genomic hybridization in clinical cytogenetics. Am J Hum Genet 1995; 57: 1211-20.
- [7] Chang CC, Shidham VB. Molecular genetics of pediatric soft tissue tumors: clinical application. J Mol Diagn 2003; 5: 143-54.
- [8] Savola S, Klami A, Tripathi A, Niini T, Serra M, Picci P, Kaski S, Zambelli D, Scotlandi K, Knuutila S. Combined use of expression and CGH arrays pinpoints novel candidate genes in Ewing sarcoma family of tumors. BMC Cancer 2009; 9: 1-17.
- [9] Delattre O, Zucman J, Melot T, Garau XS, Zucker JM, Lenoir GM, Ambros PF, Sheer D, Turc-Carel C, Triche TJ, et al. The Ewing family of tumors—a subgroup of small-round-cell tumors defined by specific chimeric transcripts. N Engl J Med 1994; 331: 294-299.
- [10] Zhang D, Jiang F, Wang X, Li G. Downregulation of ubiquitin-specific protease 22 inhibits proliferation, invasion, and epithelial-mesenchymal transition in osteosarcoma cells. Oncol Res 2017; 25: 763-771.
- [11] Jones EA, Kananurak A, Bevins CL, Hollox EJ, Bakaletz LO. Copy number variation of the beta defensin gene cluster on chromosome 8p influences the bacterial microbiota within the nasopharynx of otitis-prone children. PLoS One 2014; 9: e98269.
- [12] Hollox EJ, Armour JA, Barber JC. Extensive normal copy number variation of a beta-defensin antimicrobial-gene cluster. Am J Hum Genet 2003; 73: 591-600.
- [13] Zhao G, Bae JY, Zheng Z, Park HS, Chung KY, Roh MR, Jin Z. Overexpression and implications of melanoma-associated antigen A12 in pathogenesis of human cutaneous squamous cell carcinoma. Anticancer Res 2019; 39: 1849-1857.
- [14] Wu J, Wang J, Shen W. Identification of MA-GEA12 as a prognostic outlier gene in gastric cancers. Neoplasma 2017; 64: 238-243.
- [15] Kouprina N, Noskov VN, Solomon G, Otstot J, Isaacs W, Xu J, Schleutker J, Larionov V. Mutational analysis of SPANX genes in families with X-linked prostate cancer. Prostate 2007; 67: 820-8.
- [16] Maine EA, Westcott JM, Prechtl AM, Dang TT, Whitehurst AW, Pearson GW. The cancer-testis antigens SPANX-A/C/D and CTAG2 promote breast cancer invasion. Oncotarget 2016; 7: 14708-26.

- [17] De Paula VS, Gomes NS, Lima LG, Miyamoto CA, Monteiro RQ, Almeida FC, Valente AP. Structural basis for the interaction of human β-defensin 6 and its putative chemokine receptor CCR2 and breast cancer microvesicles. J Mol Biol 2013; 425: 4479-95.
- [18] Xu D, Zhang B, Liao C, Zhang W, Wang W, Chang Y, Shao Y. Human beta-defensin 3 contributes to the carcinogenesis of cervical cancer via activation of NF-κB signaling. Oncotarget 2016; 7: 75902-75913.
- [19] Nothwang HG, Rensing C, Kübler M, Denich D, Brandl B, Stubanus M, Haaf T, Kurnit D, Hildebrandt F. Identification of a novel Ran binding protein 2 related gene (RANBP2L1) and detection of a gene cluster on human chromosome 2q11-q12. Genomics 1998; 47: 383-92.
- [20] Lin X, Wang J, Yun L, Jiang S, Li L, Chen X, Li Z, Lu Q, Zhang Y, Ma X. Association between LE-KR1-CCNL1 and IGSF21-KLHDC7A gene polymorphisms and diabetic retinopathy of type 2 diabetes mellitus in the Chinese Han population. J Gene Med 2016; 18: 282-287.
- [21] Mamaeva OA, Kim J, Feng G, McDonald JM. Calcium/calmodulin-dependent kinase II regulates notch-1 signaling in prostate cancer cells. J Cell Biochem 2009; 106: 25-32.
- [22] Rodriguez-Bravo V, Pippa R, Song WM, Carceles-Cordon M, Dominguez-Andres A, Fujiwara N, Woo J, Koh AP, Ertel A, Lokareddy RK, Cuesta-Dominguez A, Kim RS, Rodriguez-Fernandez I, Li P, Gordon R, Hirschfield H, Prats JM, Reddy EP, Fatatis A, Petrylak DP, Gomella L, Kelly WK, Lowe SW, Knudsen KE, Galsky MD, Cingolani G, Lujambio A, Hoshida Y, Domingo-Domenech J. Nuclear pores promote lethal prostate cancer by increasing POM121-Driven E2F1, MYC, and AR nuclear import. Cell 2018; 174: 1200-1215.
- [23] Savas S, Hyde A, Stuckless SN, Parfrey P, Younghusband HB, Green R. Serotonin transporter gene (SLC6A4) variations are associated with poor survival in colorectal cancer patients. PLoS One 2012; 7: e38953.
- [24] De Summa S, Graziano F, Pilato B, Pinto R, Danza K, Lacalamita R, Serratì S, Sambiasi D, Grassi M, Tommasi S. Six low-penetrance SNPs for the estimation of breast cancer heritability: a family-based study in caucasian Italian patients. Oncol Lett 2017; 14: 4384-4390.
- [25] Suh S, Kim YH, Goh TS, Jeong DC, Lee CS, Jang JY, Cha W, Han ME, Kim SJ, Kim IJ, Pak K. mRNA expression of SLC5A5 and SLC2A family genes in papillary thyroid cancer: an analysis of the cancer genome Atlas. Yonsei Med J 2018; 59: 746-753.

- [26] Nakano N, Sakashita S, Matsuoka R, Murata Y, Shiba-Ishii A, Kobayashi N, Sato Y, Noguchi M. Cyclophilin A expression and its prognostic significance in lung adenocarcinoma. Pathol Int 2017; 67: 555-563.
- [27] Oh Y, Jeong K, Kim K, Lee YS, Jeong S, Kim SS, Yoon KS, Ha J, Kang I, Choe W. Cyclophilin B protects SH-SY5Y human neuroblastoma cells against MPP(+)-induced neurotoxicity via JNK pathway. Biophys Res Commun 2016; 478: 1396-402.
- [28] Meng DQ, Li PL, Xie M. Expression and role of cyclophilin B in stomach cancer. Genet Mol Res 2015; 14: 5346-54.
- [29] Ray P, Sullenger BA, White RR. Further characterization of the target of a potential aptamer biomarker for pancreatic cancer: cyclophilin B and its posttranslational modifications. Nucleic Acid Ther 2013; 23: 435-42.
- [30] Fang F, Zheng J, Galbaugh TL, Fiorillo AA, Hjort EE, Zeng X, Clevenger CV. Cyclophilin B as a co-regulator of prolactin-induced gene expression and function in breast cancer cells. J Mol Endocrinol 2010; 44: 319-29.
- [31] Lee J, Kim SS. An overview of cyclophilins in human cancers. J Int Med Res 2010; 38: 1561-74.
- [32] Bonanno L, Costa C, Majem M, Sanchez JJ, Rodriguez I, Gimenez-Capitan A, Molina-Vila MA, Vergnenegre A, Massuti B, Favaretto A, Rugge M, Pallares C, Taron M, Rosell R. Combinatory effect of BRCA1 and HERC2 expression on outcome in advanced non-small-cell lung cancer. BMC Cancer 2016; 16: 312.
- [33] Pham QT, Oue N, Sekino Y, Yamamoto Y, Shige-matsu Y, Sakamoto N, Sentani K, Uraoka N, Yasui W. TDO2 Overexpression is associated with cancer stem cells and poor prognosis in esophageal squamous cell carcinoma. Oncology 2018; 95: 297-308.
- [34] Bai WX, Gao J, Qian C, Zhang XQ. A bioinformatics analysis of differentially expressed genes associated with liver cancer. Zhonghua Gan Zang Bing Za Zhi 2017; 25: 435-439.